Immunotherapy has the power to become a cure for all cancers—already working to successfully treat some previously incurable cancers.
Immunotherapy promises to change the lives of all people affected by cancer. Get to know the unique benefits of cancer immunotherapy below.
Cancer immunotherapy—treatments that harness and enhance the innate powers of the immune system to fight cancer—represents the most promising new cancer treatment approach since the development of the first chemotherapies in the 1940s.
For more than 60 years, the Cancer Research Institute (CRI) has been the pioneer in advancing this new class of treatment.
Learn About CRI's Impact
Immunotherapy enables the immune system to recognize, target, and eliminate cancer cells, wherever they are in the body, making it a universal answer to cancer.
Immunotherapy is an effective treatment for patients with certain types of cancer that have been resistant to chemotherapy and radiation treatment, and has also been approved as a first line of treatment in several cancers. It may be given alone or in combination with other cancer treatments.
Immunotherapy can “train” the immune system to remember cancer cells. This “immunomemory” may result in longer-lasting and potentially permanent protection against cancer recurrence.
Clinical studies on long-term overall survival have shown that the beneficial responses to cancer immunotherapy treatment are durable—that is, they can be maintained even after treatment is completed.
Immunotherapy treatment harnesses the body's natural strength to fight cancer—empowering the immune system to conquer more types of cancer and save more lives.
See How Your Immune System Works
As a science-first organization dedicated to supporting cancer immunotherapy research, we're funding a future that fights back against cancer—all with your help.
Support our mission to cure ALL cancers, for good.
Join Team CRI by supporting our many dedicated fundraisers.
Create a profile and fill out a questionnaire to identify immunotherapy clinical trials you may be eligible for.
CALLING HOURS | M-F 8:30 a.m. to 6 p.m. ET
Se habla espanol
Request a call from a Clinical Trial Navigator
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Day 4 at AACR18 was a special day for CRI’s Dr. Antoni Ribas, and highlighted his and others’ efforts to overcome resistance to PD-1 therapy as well as insights into the role of dendritic cells.
Day 3 of AACR18 highlighted potentially “practice-changing” immunotherapy breakthroughs in lung cancer, and insights into the factors governing immunotherapy’s effectiveness in several other cancer types